FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts or other Tissue Factor (TF)-expressing cells to prevent IBMIR-mediated blood clotting.

This patent application addresses a critical challenge in cell therapy: the risk of instant IBMIR, which can lead to complications such as complement activation, immune cell infiltration, platelet adhesion and coagulation (clotting) that endanger the effectiveness and safety of cell-based treatment. Reducing inflammatory and coagulative responses has the potential to transform therapeutic protocols for intravascular, subcutaneous, and intraperitoneal cell administration and could provide safer and more effective treatments for patients worldwide.

"This patent application describes how we may be able to improve cell therapies by reducing adverse events and rejection by the body's immune system, potentially eliminating blood clotting triggered by the body's inflammatory response," said Pete O'Heeron, Founder & Chief Executive Officer of FibroBiologics.

"This approach harnesses the natural properties of fibroblasts and other TF-expressing cells to minimize the risks of, and overcome, IBMIR, a well-known limitation in cell therapy treatments," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. "By reducing the inflammatory responses to therapeutic cells, we have developed a unique approach that can make cell therapy treatments potentially safer and more effective. This advancement exemplifies our goal to transform what is possible in the cell therapy space."

For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of fibroblasts and TF-expressing cells to reduce inflammatory and coagulative responses and adverse events, to potentially eliminate blood clotting triggered by the body’s inflammatory response, to potentially transform therapeutic protocols, to provide safer and more effective treatments, to minimize the risks of, and overcome, IBMIR, and to transform what is possible in the cell therapy space. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

Released November 14, 2024